Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:42:35.741Z.
Calculation as of: 2026-10-06T14:42:35.741Z.
Quote observation: 2026-10-06T14:39:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d8f500f051b8c2f6d9df2326c38ce0bcf8edb39987555b97daf7c0f1a95d0fd4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
LENZ Therapeutics, Inc.
Market Cap
$117.11M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $117.11M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.21M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.72M | N/A |
| Genelux Corporation (GNLX)vs › | $114.34M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.23M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.22M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $111.93M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $111.86M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
